Mirum's Brelovitug meets goal in Phase III AZURE-1 study

Mirum's Brelovitug meets goal in Phase III AZURE-1 study: the analysis positions MIRM, MDGL and BMRN to benefit and VIR, ABUS and PFE under pressure; confidence high.

Analyzed 2026-09-29 — point-in-time, never revised. Outcomes are scored against SPY and published either way.

Ranked exposures

▲ MIRM Mirum — impact +90 · confidence high · horizon immediate · 1st order
Mirum gains an approvable path for brelovitug after AZURE-1's success, expanding future hepatitis delta treatment revenue.
Chain: Phase III AZURE-1 primary endpoint met → brelovitug gains an approvable regulatory path → filing supports launch in chronic hepatitis delta → new product revenue adds to bile acid franchise
What would break the call: An FDA complete response letter or a safety signal in the label blocks the launch.
▼ VIR Vir Biotechnology — impact -70 · confidence low · horizon immediate · 2nd order
Vir faces a validated rival reaching market first, which compresses the commercial opportunity for its tobevibart and elebsiran combination.
Chain: rival hepatitis delta antibody clears Phase III → Mirum reaches regulators ahead of tobevibart → first mover captures hepatology prescribers and payer slots → Vir peak sales and partnering leverage shrink
What would break the call: Vir reports superior functional cure rates and files first, restoring its lead position.
▲ MDGL Madrigal — impact +32 · confidence low · horizon weeks · 3rd order
Madrigal increases projected sales volume for its liver drug as positive liver trial lifts sector confidence.
Chain: positive liver trial lifts hepatology sector sentiment → investors reprice liver disease commercial assumptions → screening and hepatologist engagement broadens → Madrigal benefits from higher liver clinic traffic
What would break the call: Rezdiffra script trends decelerate, showing hepatology sentiment does not drive Madrigal volume.
▼ ABUS Arbutus Biopharma — impact -30 · confidence low · horizon weeks · 2nd order
Arbutus sees partnering value for its hepatitis B and delta assets fall as investors back the proven antibody approach.
Chain: antibody mechanism validated in hepatitis delta → capital rotates toward proven modality → Arbutus RNAi and capsid assets look less differentiated → partnering terms and milestone value weaken
What would break the call: Arbutus signs a large hepatitis B partnership with rich upfront terms.
▼ PFE Pfizer — impact -28 · confidence low · horizon quarters · 3rd order
Pfizer records lower sales volume in specialty liver drugs as brelovitug diverts patient treatments away from its offerings.
Chain: new hepatitis delta therapy enters specialty channel → hepatology budgets shift toward the new agent → competing specialty liver products lose share → Pfizer specialty volume declines slightly
What would break the call: Pfizer specialty revenue grows through the launch period, showing no channel displacement.
▼ ASMB Assembly Bio — impact -25 · confidence low · horizon quarters · 2nd order
Assembly must clear a higher efficacy bar for its hepatitis programs, raising trial costs and delaying partnership economics.
Chain: efficacy benchmark rises in viral hepatitis → regulators and partners demand stronger endpoint data → Assembly runs larger and longer trials → research expense rises and partnership economics slip
What would break the call: Assembly reports strong functional cure data that clears the raised bar.
▼ SNY Sanofi — impact -24 · confidence low · horizon quarters · 3rd order
Sanofi reduces its expected margins after new competition from brelovitug impacts sales of its enzyme replacement therapies.
Chain: rare disease approval standards reset upward → payers scrutinize legacy rare disease pricing → enzyme replacement contracts renegotiated → Sanofi specialty care margin compresses modestly
What would break the call: Sanofi rare disease pricing holds flat in the next two reported quarters.
▼ ALGS Aligos Therapeutics — impact -22 · confidence low · horizon quarters · 2nd order
Aligos competes for the same specialists and trial sites, slowing enrollment and weakening licensing terms for its hepatitis candidates.
Chain: competitor validates hepatitis delta treatment approach → trial sites and specialists prioritize the winner → Aligos enrollment slows and costs rise → licensing terms for hepatitis candidates weaken
What would break the call: Aligos announces a hepatitis partnership with a large pharmaceutical buyer.
▲ BMRN BioMarin — impact +22 · confidence low · horizon weeks · 3rd order
BioMarin achieves higher pricing for its rare disease products after the trial success sets new standard for approval.
Chain: rare disease trial success renews investor interest → risk appetite for orphan assets improves → payers accept premium orphan pricing precedent → BioMarin pricing assumptions hold firmer
What would break the call: BioMarin guides to lower net pricing on rare disease products next quarter.
▼ MRK Merck — impact -19 · confidence low · horizon weeks · 3rd order
Merck encounters pricing pressure on its rare disease lineup after the Phase III success introduces additional market competition.
Chain: additional specialty competitor enters liver market → payer formularies gain negotiating leverage → rebates increase across specialty categories → Merck realized net price edges lower
What would break the call: Merck reports stable specialty net pricing with no incremental rebate pressure.
▼ DTIL Precision BioSciences — impact -18 · confidence low · horizon weeks · 2nd order
Precision faces tougher efficacy benchmarks for its hepatitis B gene editing program, pushing partnership milestones further into the future.
Chain: antibody therapy sets higher viral suppression bar → gene editing programs must beat that benchmark → Precision faces longer preclinical and clinical timelines → partnership milestone payments move later
What would break the call: Precision posts clinical data showing durable surface antigen loss in hepatitis B.
▲ DGX Quest Diagnostics — impact +18 · confidence low · horizon quarters · 2nd order
Quest processes more hepatitis delta antibody and RNA confirmatory tests as physicians screen hepatitis B patients for treatable coinfection.
Chain: treatable hepatitis delta creates reason to screen → guidelines push reflex testing in hepatitis B patients → antibody and RNA test orders rise → Quest specialty testing volume and revenue increase
What would break the call: Hepatology guidelines leave hepatitis delta screening optional after the approval.
▲ REGN Regeneron — impact +18 · confidence low · horizon quarters · 3rd order
Regeneron accelerates development spending on rare disease assets after the AZURE-1 study outcome validates new mechanisms.
Chain: antibody mechanism validated in rare viral disease → internal programs gain perceived value → Regeneron raises rare disease research spending → near term expense rises before revenue
What would break the call: Regeneron guides research spending flat with no new liver disease programs.
▼ BMY Bristol — impact -17 · confidence low · horizon weeks · 3rd order
Bristol sees declining revenue in its portfolio after the study outcome advances a rival product to market faster.
Chain: competitor product reaches specialty liver market → hepatology prescribing budget reallocates → Bristol adjacent specialty volume slips → revenue growth trims at the margin
What would break the call: Bristol specialty portfolio volumes grow through the brelovitug launch window.
▲ LH Labcorp — impact +17 · confidence low · horizon quarters · 2nd order
Labcorp books incremental specialty testing volume because a viable treatment turns hepatitis delta screening into routine hepatology practice.
Chain: approved therapy makes hepatitis delta worth finding → hepatologists add reflex testing to hepatitis B workups → Labcorp esoteric test requisitions increase → specialty testing revenue and mix improve
What would break the call: Screening stays concentrated in academic centers with in house testing capability.
▲ QGEN Qiagen — impact +15 · confidence low · horizon quarters · 2nd order
Qiagen sells more molecular assays and sample preparation kits as laboratories add hepatitis delta RNA quantification to standard panels.
Chain: hepatitis delta RNA quantification enters routine panels → labs validate and run molecular assays → demand rises for kits and sample prep → Qiagen consumables revenue grows
What would break the call: Competing assay platforms capture the hepatitis delta RNA testing market instead.
▲ VRTX Vertex — impact +15 · confidence low · horizon quarters · 3rd order
Vertex raises research investment in genetic and liver disorders following the successful Phase III outcome for brelovitug.
Chain: rare disease trial validates targeted approach → sector risk appetite for orphan programs improves → Vertex accelerates liver and genetic disease research → spending rises ahead of any revenue
What would break the call: Vertex reprioritizes away from liver disease in its next pipeline update.
▼ GILD Gilead — impact -13 · confidence medium · horizon quarters · 2nd order
Gilead loses United States hepatitis delta treatment share as a stronger competitor captures the market.
Chain: brelovitug targets chronic hepatitis delta directly → bulevirtide faces a validated antibody competitor → Gilead loses share in hepatitis delta → liver disease franchise growth slows
What would break the call: Bulevirtide secures United States approval first with a strong long term dataset.
▼ ALNY Alnylam Pharmaceuticals — impact -12 · confidence low · horizon quarters · 3rd order
Alnylam originated elebsiran and earns milestones and royalties from Vir, so a faster rival trims that future stream.
Chain: brelovitug beats Vir combination to market → Vir hepatitis delta commercial value falls → elebsiran milestone and royalty potential shrinks → Alnylam partnered revenue expectation declines
What would break the call: Vir reports functional cure data that secures its own hepatitis delta approval.
▲ ABT Abbott — impact +12 · confidence low · horizon quarters · 2nd order
Abbott expands sales of viral hepatitis immunoassays running on its diagnostic analyzers as coinfection screening widens across hospital laboratories.
Chain: hepatitis delta becomes treatable and screenable → hospital labs widen coinfection immunoassay testing → Abbott analyzers run more hepatitis panels → diagnostics consumable revenue increases
What would break the call: Screening shifts to molecular reference labs rather than hospital immunoassay platforms.
▲ RGEN Repligen — impact +12 · confidence low · horizon quarters · 3rd order
Repligen supplies filtration and chromatography consumables used when antibody manufacturing scales up for a commercial hepatitis delta launch.
Chain: approval requires commercial antibody manufacturing scale → Mirum and partners expand bioprocessing capacity → demand rises for filtration and chromatography consumables → Repligen bioprocessing orders increase
What would break the call: Manufacturing uses competing filtration suppliers or existing idle capacity instead.
▼ ENTA Enanta Pharmaceuticals — impact -10 · confidence low · horizon quarters · 3rd order
Enanta antiviral programs compete for the same investor capital and specialist sites, weakening its partnering leverage in hepatology.
Chain: antibody approach validated in viral hepatitis → investor capital favors proven modalities → Enanta antiviral assets look less differentiated → partnering and financing terms weaken
What would break the call: Enanta posts strong respiratory antiviral data that attracts a major partner.
▲ COR Cencora — impact +10 · confidence low · horizon quarters
Cencora captures specialty logistics revenue because rare liver disease biologics move through its limited distribution and patient support networks.
▲ MCK McKesson — impact +10 · confidence low · horizon quarters
McKesson earns distribution and specialty pharmacy fees on each shipment of a costly injectable biologic reaching rare disease patients.

Sources

What happened

Horizon	Verdict	Top pick	Excess vs SPY
1 trading days	Wrong	MIRM	-0.3% vs SPY
5 trading days	Wrong	MIRM	-8.6% vs SPY

Related scenarios

Stocks in this scenario

MIRM · VIR · MDGL · ABUS · PFE · ASMB · SNY · ALGS · BMRN · MRK · DTIL · DGX · REGN · BMY · LH · QGEN · VRTX · GILD · ALNY · ABT · RGEN · ENTA · COR · MCK · TMO · IQV · WST

News events · All scenarios · Pricing · Track record · Methodology · Map your own scenario